Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
537.78+2.30 (+0.43%)
At close: 4:00PM EST
| Previous close | 535.48 |
| Open | 534.10 |
| Bid | 536.88 x 1100 |
| Ask | 543.00 x 800 |
| Day's range | 534.10 - 546.72 |
| 52-week range | 328.13 - 664.64 |
| Volume | 595,502 |
| Avg. volume | 924,711 |
| Market cap | 57.384B |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | 19.71 |
| EPS (TTM) | 27.29 |
| Earnings date | 05 Feb 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 660.56 |
- Zacks
Why Regeneron (REGN) Could Beat Earnings Estimates Again
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks
Regeneron (REGN), U.S. Government Ink Deal for COVID-19 Treatment
Regeneron (REGN) inks deal with the U.S. government to sell additional 1.25 million doses (an agreement value of up to $2.625 billion) of its COVID-19 antibody cocktail.
- Zacks
Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY
The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.
© 2021 Verizon Media. All rights reserved.
